leisure time -WSS

leisure time

author：hotspot 2025-09-27 21:55:04 - browse：32

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： To avoid data mishandling cases, universities eye AI and other tools

focus

WSS

Anxious about a speech? A startup wants you to pop a minty cardiac drug

It's time to retire 'poor historian' from clinicians' vocabularies

Vaccine advisory panel ACIP left half staffed by HHS

BioAge raises $170M for combination therapy with Zepbound

Biden report: The neurospychology of memory and aging

Medicare threatens to cut off funding for HCA's Mission hospital

explore

leisure time

Wikipedia

Medical records are filled with copy

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Medicare proposal to cover medical devices draws a mixed reaction

Gilead might be held responsible for not developing a drug

Heart attack and stroke risk calculators need revising

Case highlights the risks of experimental stem cell therapy

Moonlake's readout produced a cash windfall. Risks remain

Why did Pfizer dish out millions for a Super Bowl ad?

The high cost of giving birth even with insurance

Helping hospitals and community health centers plan for resilience

focus

Big Tobacco's 'harm reduction': Is it for real, or a sham?

The Readout: Gilead, Bernie Sanders, and other pharma news

Arc Institute generative AI designs new CRISPR systems

Robert F. Kennedy is pitching centrism on health, even on abortion

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Medicare threatens to cut off funding for HCA's Mission hospital

focus

focus

focus

Wikipedia